Shares of Aveo Pharmaceuticals (AVEO) fall 17% premarket as the FDA asks the Oncologic Drugs...

|About: AVEO Pharmaceuticals, Inc. (AVEO)|By:, SA News Editor

Shares of Aveo Pharmaceuticals (AVEO) fall 17% premarket as the FDA asks the Oncologic Drugs Advisory Committee to help evaluate whether a single randomized trial is sufficient to warrant marketing approval for AVEO's renal cell carcinoma treatment tivozanib or whether further testing is necessary.